Sandra Ihne

Dr. Sandra Ihne


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMax Steinhardt
Max Steinhardt
VCVladimir Cejka
Vladimir Cejka
MCMengmeng Chen
Mengmeng Chen
SBSabrina Bäuerlein
Sabrina Bäuerlein
JSJulia Schäfer
Julia Schäfer
Stefan StörkStefan Störk
Stefan Störk
Sodium-glucose transport protein 2 inhibitors (SGLT2i) slow the progression of renal dysfunction and improve the prognosis of patients with heart failure. Amyloidosis constitutes an important subgroup for which evidence is lacking. Amyloidotic fibrils originating from misfolded transthyretin and light chains are the causal agents in ATTR and AL amyloidosis. In these most frequent subtypes, cardiac involvement is the most common organ manifestation. Because cardiac and renal function frequently deteriorate over time, even under best available treatment, SGLT2i emerge as a promising treatment option due to their reno- and cardioprotective properties. We retrospectively analyzed patients with cardiac amyloidosis, who received either dapagliflozin or empagliflozin. Out of 79 patients, 5.1% had urinary tract infections; 2 stopped SGLT2i therapy; and 2.5% died unrelated to the intake of SGLT2i. No genital mycotic infections were observed. As expected, a slight drop in the glomerular filtration rate was noted, while the NYHA functional status, cardiac and hepatic function, as well as the 6 min walk distance remained stable over time. These data provide a rationale for the use of SGLT2i in patients with amyloidosis and concomitant cardiac or renal dysfunction. Prospective randomized data are desired to confirm safety and to prove efficacy in this increasingly important group of patients.

Verified
Journal Article
Open access
PDF file
SISandra Ihne
Sandra Ihne
OGOliver Goetze
Oliver Goetze
FGFelix Gerstendörfer
Felix Gerstendörfer
FSFloran Sahiti
Floran Sahiti
ISIna Schade
Ina Schade
AGAndreas Geier
Andreas Geier
Background: Congestion is associated with poor prognosis in cardiac amyloidosis (CA). The cardio-hepatic interaction and the prognostic impact of secondary liver affection by cardiac congestion in CA are poorly understood and require further characterisation. Methods: Participants of the amyloidosis cohort study AmyKoS at the Interdisciplinary Amyloidosis Centre of Northern Bavaria with proven transthyretin (ATTR-CA) and light chain CA (AL-CA) underwent serial work-up including laboratory tests, echocardiography, and in-depth hepatic assessment by vibration-controlled transient elastography (VCTE) and 13C-methacetin breath test. Results: In total, 74 patients with AL-CA (n = 17), ATTR-CA (n = 26) and the controls (n = 31) were analysed. ATTR-CA patients showed decreased microsomal liver function expressed by maximal percentage of dose rate (PDRpeak) related to hepatic congestion. Reduced PDRpeak in AL-CA could result from altered pharmacokinetics due to changed hepatic blood flow. Liver stiffness as a combined surrogate of chronic liver damage and congestion was identified as a predictor of all-cause mortality. Statistical modelling of the cardio-hepatic interaction revealed septum thickness, NT-proBNP and PDRpeak as predictors of liver stiffness in both CA subtypes; dilatation of liver veins and the fibrosis score FIB-4 were only significant for ATTR-CA. Conclusions: Non-invasive methods allow us to characterise CA-associated hepatic pathophysiology. Liver stiffness might be promising for risk stratification in CA.

20 May 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SISandra Ihne
Sandra Ihne
MLMaria Leberzammer
Maria Leberzammer
MWMarcel Weidgans
Marcel Weidgans
SFStefan Frantz
Stefan Frantz
HEHermann Einsele
Hermann Einsele
SNSilke Neuderth
Silke Neuderth
Amyloidosis is a rare multi-system disorder associated with frequently delayed diagnosis, enormous disease burden and psychosocial distress. Systematic assessment of needs was performed by a subtype-spanning questionnaire-based survey within the AMY-NEEDS research and care program. 118 patients with proven amyloidosis (62.7% ATTR, 22.0% AL, 15.3% other forms) were included in August 2020 until February 2021 (mean age 71.2 ±11.3 years; 30% women). The median diagnostic delay between onset of symptoms and diagnosis was 9.0 (range: 2.5; 33.0) months. Local health care providers (HCPs) play a central role on the way to diagnosis. Diagnosis itself typically requires a clinical but not necessarily a university setting. In the treatment phase, the focus moves to the amyloidosis centre as primary contact and coordinator, with general practitioners (GPs) acting predominantly as a contact point in crisis and link to additional services. About half of patients reported impaired quality of life and one third suffering from anxiety and depressed mood, respectively. The majority of patients talk about their concerns with close caregivers and local HCPs. Advance care planning is a relevant, yet insufficiently met need. The journey of patients with amyloidotic disease, their contact partners and needs at different stages were characterized in detail within the German health care system. An amyloidosis-specific care concept has to master the multitude of interfaces connecting the numerous treatment providers involved with the amyloidosis centre and GPs as key players. Telemedical approaches could be a promising and well-accepted option allowing optimal coordination and communication.

10 February 2024 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SISandra Ihne
Sandra Ihne
TRTeresa Radovic
Teresa Radovic
SFSaskia Fries
Saskia Fries
SFStefan Frantz
Stefan Frantz
HEHermann Einsele
Hermann Einsele
SNSilke Neuderth
Silke Neuderth
Background: Amyloidosis represents a rare yet heterogeneous multi-system disorder associated with a grave prognosis and an enormous psycho-emotional strain on patients, relatives, and caregivers. We here present the overall study design and first results of AMY-NEEDS, a research program aiming to systematically assess the needs of patients suffering from amyloidosis, their relatives and health care professionals (HCPs), and develop an amyloidosis-specific care approach. Methods: AMY-NEEDS uses a mixed-methods approach including focus groups (step 1), a questionnaire-based broad evaluation within the local amyloidosis patient collective (step 2), and the development of a needs-adapted care concept (step 3). Results: Seven patients, six relatives and five HCPs participated in the focus groups (step 1). At the time of diagnosis, patients expressed the need of a smooth diagnostic process, possibly enhanced through improved awareness and better education of local HCPs. There was a strong wish to receive well-founded information and comprehensive support including companionship during medical visits, experience the feeling of being understood, find trust in that “everything possible” is being done, and have effortless access to centre staff. In the course of the disease, patients favoured that the specialized centre should manage treatment coordination, monitoring and psychosocial support. The interface between centre and local HCPs was regarded of particular importance, requiring further investigation into its optimal design. Conclusions: Patients with amyloidosis express particular needs that should appropriately be considered in specifically tailored care concepts.

2 February 2022 in Amyloid
Verified
Journal Article
Closed access
SISandra Ihne
Sandra Ihne
MKMalte Kircher
Malte Kircher
APAikaterini Papagianni
Aikaterini Papagianni
OGOliver Goetze
Oliver Goetze
CMCaroline Morbach
Caroline Morbach
SSStefan Störk
Stefan Störk
AA amyloidosis is a rare long-term complication of insufficiently controlled chronic inflammatory syndromes [1] that may occur in the context of malignancies. In September 1990, a female patient, a...

2 February 2024 in Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SISandra Ihne
Sandra Ihne
CMCaroline Morbach
Caroline Morbach
APAikaterini Papagianni
Aikaterini Papagianni
VCVladimir Cejka
Vladimir Cejka
MSMaximilian Johannes Steinhardt
Maximilian Johannes Steinhardt
HEHermann Einsele
Hermann Einsele
Purpose: Systemic amyloidosis represents a yet poorly characterized complex and multifaceted rare multisystem disease with high mortality. Clinical presentation, clinical course, and treatment vary within and across subtypes. Established biomarkers are predominantly non-specific. Diagnosis and management of these patients require specifically tailored interdisciplinary structures. Well-characterized patient cohorts are needed to optimize diagnostic tools and treatment options. Method: The prospective cohort study AmyKoS was established as a monocentric observational study for patients with suspected and proven systemic and localized amyloidosis at the Interdisciplinary Amyloidosis Centre of Northern Bavaria in 2018. We here describe the study rationale and design based on the underlying clinical structures. The primary aim is to establish a large in-detail characterized patient population with appropriate biomaterial resources. The primary endpoint is overall survival; secondary endpoints are disease-associated complications, prevalence and incidence of ICD-10-coded psychological disorders and characterization of organ involvement and response. Results/conclusions: AmyKoS serves as an umbrella structure for clinical and translational research. It differs at least partly from other amyloidosis cohort studies by its cross-subtype approach and is unique regarding the inclusion of patients under suspicion regardless of confirmation of amyloidosis. Therefore, AmyKoS simultaneously generates a negative control group for the evaluation of diagnostic markers and methods and allows to test their generalizability to all subtypes. As a special feature, the multi-step AMY-NEEDS substudy systematically evaluates the established structures with the aim of improving patient-orientated care and the interfaces with referring physicians. The characteristics of the AmyKoS cohort are congruent with the findings of large clinical trials.